Search for: "High v. Economics Laboratory, Inc."
Results 1 - 20
of 82
Sorted by Relevance
|
Sort by Date
7 Aug 2014, 11:23 am
In Wisekal v. [read post]
10 May 2012, 6:44 am
Defendant Mayer Laboratories, Inc. [read post]
10 May 2012, 6:44 am
Defendant Mayer Laboratories, Inc. [read post]
2 Oct 2015, 9:01 am
Blog: Temas de propiedad intelectual Víctor M. [read post]
5 Apr 2007, 5:35 pm
Jensen Enterprises, Inc. v. [read post]
8 Oct 2012, 2:03 pm
Fortunately, New Jersey offers relief from such acts, as discussed in the recent Appellate Division case of Baseline Services, Inc. v. [read post]
16 Oct 2014, 8:16 am
The California Court of Appeal, in Altavion, Inc. v. [read post]
15 Apr 2010, 9:20 am
Cir. 1996) (not an FDCA case); Mylan Laboratories, Inc. v. [read post]
27 Apr 2022, 5:51 am
Reliaguard, Inc., 2022 WL 1157481, No. [read post]
26 Jun 2012, 6:45 am
Prometheus Laboratories, Inc. [read post]
7 Jul 2011, 2:31 pm
March 28, 1997) (reaffirming PTO 12 in light of Medtronic, Inc. v. [read post]
26 Apr 2015, 6:14 pm
It is a tool to promote innovation which in turn helps the economic system. [read post]
14 Jun 2015, 10:02 pm
Prometheus Laboratories, Inc., 132 S. [read post]
22 Apr 2010, 3:51 am
Paddock Laboratories, Inc. [read post]
29 Dec 2010, 12:54 pm
Wyeth, Inc. v. [read post]
18 Dec 2022, 3:52 pm
The industry now has an economic ally and adjunct in the litigation finance industry, and it has been boosted by the desuetude of laws against champerty and maintenance. [read post]
22 Jan 2009, 2:06 am
Wyeth, Inc., 168 Cal. [read post]
28 Apr 2013, 10:39 pm
Finally, Prashant has reported just some time back on yet another piece of pharmaceutical legislation in India, wherein Symed Labs Ltd. has sued Glenmark Pharmaceuticals Laboratories before the Delhi High Court for allegedly infringing two of its patents, granted for “Novel intermediates for linezolid and related compounds” and for “A novel process for the preparation of linezolid and related compounds” respectively. [read post]
18 Jan 2013, 2:06 pm
(citations omitted).Third, the economic incentives are all wrong, as non-manufacturer liability rewards questionable practices by generic manufacturers and penalizes more careful competitors:Careful Drug Co. gets word from the field that its drug, “X”, might cure high blood pressure when a doctor comes to it with a case series. [read post]
28 Dec 2012, 1:57 pm
Centocor, Inc. v. [read post]
